Concomitant chemotherapy with reirradiation offers a cure for select patients with recurrent head and neck cancer in a previously irradiated area. With the findings of 2-year survival in 25% of patients, the researchers noted the importance of choosing the correct patients for this therapy. Previous concurrent chemoradiotherapy was associated with poor survival outcomes. In addition, there was significant risk of sever toxicity, with 20% of patients experiencing treatment-related death.
The complete study is published online in the journal Cancer (http://onlinelibrary.wiley.com/doi/10.1002/cncr.26084/abstract).
To sign up for our newsletter or print publications, please enter your contact information below.
